People

Oncology imaging, including imaging of paediatric neuroendocrine tumours

Radiotherapy using unsealed sources of radiation

SPECT technology and image reconstruction

MR technology

Electrophysiology equipment

Visual development in preterm, newborn and infants

Objective assessment of visual acuity

Signal detection

Modelling visual impairment

I am a Radiochemist with experience in both SPECT and PET chemistry. Before I came to Glasgow, I worked for many years as both a radiochemist and a synthetic chemist in the radiopharmaceutical industry. My interests are using radiotracers to look at changes in biological chemistry in disease. As such, I’m interested in the development of novel radiotracers, which is a multi-disciplinary process bringing together chemistry, radiochemistry and biology, and the translation of such new tracers from a pre-clinical phase into the clinic. I’m also interested in the clinical applications of new and existing radiotracers, in which I collaborate with colleagues in Clinical Physics and Psychological Medicine. Beyond the development and use of tracers, I’m interested in the development of radiolabelling and purification methods

Dr Pimlott is the principal radiochemist in the research and development radiopharmaceutical group, based at the Radionuclide Dispensary, Western Infirmary, Glasgow. Her research is focused on the development of novel molecular imaging agents. This includes:-

• the development of novel radiolabelling methodologies
• the synthesis and evaluation of novel tracer candidates using both in vitro and in vivo imaging techniques
• the development of novel in vitro methodologies for the prediction of radiotracer in vivo characteristics.

Dr Pimlott is also experienced in the provision of radiopharmaceuticals for clinical research studies in compliance with Good Manufacturing Practice standards. Research is funded by the SINAPSE, Wellbeing of Women, Translational Medicine Research Collaboration (TMRC), Neurosciences Foundation, Chief Scientist Office (Scottish Executive), Medical Research Scotland and GE Healthcare.

My current interest include; the late life imaging correlates of early life conditions and experiences; the imaging correlates on cognitive reserve; the use of entropy to measure adaptive capacity in the brain; imaging the non cognitive aspects of dementia and the influence of TAU aggregation inhibition on brain function and structure

CT coronary angiography, myocardial perfusion imaging, magnetic resonance angiography, molecular imaging in cardiovascular disease.

I am acutely aware of the cost and complexity of advanced clinical imaging technologies and am keen to bring together professionals from all sectors - health care, academia and industry - to address the challenges of using human imaging to advance our knowledge of health and disease. I have a particular interest in working with colleagues exploring the biological basis of neurological and mental health conditions. As a clinical physicist I have a focus on commercialisation of technologies developed by identifying opportunities arising from every day clinical practice. I am also an enthusiastic participant in the training and mentoring of young scientists and technologists.